Quick Takeaways
- Michael Kauffman has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,416,845.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Michael Kauffman
- Location
- Newton, MA
- Summary
- The estimated net worth of Michael Kauffman is at least $1,416,845 dollars as of 08 Jan 2026. Michael Kauffman is the Director of Karyopharm Therapeutics Inc. and owns shares of Karyopharm Therapeutics Inc. (KPTI) stock worth about $1.32M. Michael Kauffman is the President of Development, Director of Verastem, Inc. and owns shares of Verastem, Inc. (VSTM) stock worth about $86.7K. Michael Kauffman is the Director of Adicet Bio, Inc. and owns shares of Adicet Bio, Inc. (ACET) stock worth about $8.4K.
- Signature
- /s/ Daniel Calkins, Attorney in Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Michael Kauffman and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Karyopharm Therapeutics Inc. ($1,321,748).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Michael Kauffman
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | Director | $1,321,748 | 28 Feb 2022 | ||
| VSTM | Verastem, Inc. | President of Development, Director | $86,660 | -$85,500 | -50% | 06 Jan 2026 |
| ACET | Adicet Bio, Inc. | Director | $8,437 | 21 Aug 2024 | ||
| KYNB | FIBROGEN INC | Director | 04 Jun 2025 | |||
| KZR | Kezar Life Sciences, Inc. | Director | 18 Jun 2025 |
Insider Transactions Reported by Michael Kauffman:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.